



Ablative Solutions Announces Presentations on Alcohol-Mediated Renal Denervation at the EuroPCR Congress 2016

Kalamazoo, MI, and Palo Alto, CA – May 16, 2016 – Ablative Solutions, Inc. (ASI), a privately held company headquartered in Kalamazoo, MI, with offices in Palo Alto, CA, announced today numerous presentations at the upcoming EuroPCR 2016 Congress in Paris on May 17-20. These presentations will discuss a novel approach to renal denervation based on the CE-marked **Peregrine System™ Infusion Catheter**. The Peregrine System provides targeted delivery of a neurolytic agent, such as alcohol, to treat sympathetic nerves located in the outer region of the renal arteries. The interruption of these nerve pathways may have therapeutic implications for a number of diseases and conditions, including hypertension.

Professor Wojtek Wojakowski, Poland, and Dr. Stefan Bertog, US and Germany, will be the presenters on Tuesday, Wednesday, and Thursday of the conference.

Tuesday, 17 May

13:15, Room Maillot

Renal and peripheral interventions

'Alcohol-mediated endovascular renal denervation: the PEREGRINE study' - W. Wojakowski

14:50, Room Arlequin

Mid- and long-term outcome after renal denervation

'Six-month results from the PEREGRINE study of alcohol-mediated renal denervation in refractory hypertension' - W. Wojakowski

Wednesday, 18 May

09:46, Room 342A

Critical appraisal of devices for the management of hypertension

'Alcohol-Mediated Renal Denervation Based on the Peregrine System' – S. Bertog

Thursday, 19 May

15:11, Room 241

New insights in renal denervation

'Transcatheter perivascular alcohol denervation addresses technical challenges of energy-based renal denervation' - S. Bertog

09:45, Room Arlequin

An image is worth 1,000 words

'Tough Access to the Renal Artery Intervention?'

Image 31 unveiled and key findings - W. Wojakowski

In the U.S., the Peregrine System has been 510(k) cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area; however, it is not currently cleared or approved for the treatment of hypertension.

The Peregrine System is intended for use by trained physicians familiar with the risks as detailed in the instructions for use.

The Peregrine European Post-Market Study includes multiple European clinical sites to enable additional cardiologists and hypertensionists to evaluate Targeted Perivascular Renal Denervation using the Peregrine System in their patients suffering from hypertension. For more information about Ablative Solutions, Inc. and the Peregrine System Infusion Catheter, visit ablativesolutions.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in an ASI stock offering. There will not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of ASI's products to patients, market and physician acceptance of ASI's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. ASI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information:

Vartan Ghazarossian, PhD

President

(650) 321-6884

<http://www.ablativesolutions.com>